Lytix Biopharma has appointed Jørund Sollid as Chief Business Officer
Lytix Biopharma announces that it has strengthened its management team with the appointment of Jørund Sollid, PhD, as Chief Business Officer (CBO) from October 2020.
Sollid will be responsible for the company’s corporate development activities and executing its business strategy. He will focus on strategic partnerships globally and support the executive team in securing funding for the critical path.
Dr. Sollid has for the last 12 years been working within business development, licensing and strategic partnership. He has experience from the whole asset value chain, from basic research to pre-clinical stage, clinical progression and launching and selling products, and had roles both in medical department, commercial operations and traditional business development and licensing. Prior to joining Lytix he was Head of Business Development and Licensing in Mundipharma with global business segment responsibility. Sollid holds a PhD within physiology and is a certified licensing professional.
“At this stage for the company it is important to appoint a proven executive with a high level of business experience to achieve our next set of commercial goals,” said Øystein Rekdal, CEO at Lytix Biopharma. “Jørund has gathered considerable achievements in business development both from the buy- and sell side for early stage and on-market assets, and has succeeded in bringing top-notch science into a solid commercial output. I am delighted to welcome Jørund to Lytix Biopharma and to our executive management team."
“I really wanted to join a clinical stage biotech company where I would be able to make a significant difference to the company and to patients’ outcomes. Lytixs’ technology addresses a major challenge in conditioning the immune system to better fight cancer. The recent market validation received through the elegant deal done with Verrica, further substantiates that Lytix’ products have a significant commercial potential, enough margins and a long-term market life cycle. The importance of having a company as Verrica Pharmaceuticals dedicating such a significant amount of its total operational capabilities and funds to a Lytix product cannot be overstated,” said Jørund Sollid, CBO of Lytix Biopharma. “I’m delighted to join the company and look forward to contributing to bring Lytix’ technology to the patients and the company to a commercial success.